{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    9,
    10,
    11,
    12,
    30,
    31,
    32,
    35,
    36,
    37,
    42,
    44,
    45,
    46,
    50
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Rescreening Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1",
        "sectionTitle": "Screening",
        "description": "Reference to screening procedures for subjects who were screen failures but are rescreened."
      },
      {
        "id": "ref_2",
        "name": "Prohibited Treatment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.2.2",
        "sectionTitle": "Prohibited medication",
        "description": "Cross-reference regarding the use of prohibited treatments and study discontinuation."
      },
      {
        "id": "ref_3",
        "name": "Imaging Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.2",
        "sectionTitle": "Color fundus photography and fluorescein angiography",
        "description": "Reference to independent review of images at predefined time-points."
      },
      {
        "id": "ref_4",
        "name": "OCT Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.3.3",
        "sectionTitle": "Optical coherence tomography",
        "description": "Reference to independent review of SD-OCT images."
      },
      {
        "id": "ref_5",
        "name": "IOI Safety Evaluation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4.5",
        "sectionTitle": "Ophthalmic examination",
        "description": "Reference for additional ophthalmic examination and imaging to evaluate intraocular inflammation."
      },
      {
        "id": "ref_6",
        "name": "Pregnancy Reporting Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.4.3",
        "sectionTitle": "Pregnancy",
        "description": "Reference to pregnancy reporting requirements."
      },
      {
        "id": "ref_7",
        "name": "SAE Reporting Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1.3",
        "sectionTitle": "SAE reporting",
        "description": "Reference for reporting details of serious adverse events during screening."
      },
      {
        "id": "ref_8",
        "name": "Table Reference - Assessment Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8-1",
        "sectionTitle": "Assessment Schedule",
        "description": "Internal link to the list of all assessments and visit schedules."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Two consecutive injections should be at least 21 days apart.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Visit schedule and assessments",
        "pageNumber": 38
      },
      {
        "id": "annot_2",
        "text": "PRP performed as a day case hospitalization should not be recorded as a serious adverse event (SAE) despite hospitalization.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Arm 2: PRP",
        "pageNumber": 36
      },
      {
        "id": "annot_3",
        "text": "If any signs of intraocular inflammation are present, then an IVT injection must not be performed.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Instruction for administering study treatment",
        "pageNumber": 36
      },
      {
        "id": "annot_4",
        "text": "It is recommended to receive the COVID-19 vaccine at least 7 days before or after the study treatment visit.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Other treatment(s)",
        "pageNumber": 31
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "02 (Clean)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-09-28",
        "description": "Implementation of Urgent Safety Measures (USM) regarding retinal vasculitis and retinal vascular occlusion.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_2",
        "versionNumber": "01",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-06-05",
        "description": "Clarification on safety assessments and modifications due to COVID-19 pandemic.",
        "amendmentNumber": "Amendment 1"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 4,
      "versionCount": 2
    }
  }
}